This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaspar, M. Articles by Neri, D. Search for Related Content PubMed Articles by Kaspar, M. Articles by Neri, D.

The Antibody-Mediated Targeted Delivery of Interleukin-15 and GM-CSF to the Tumor Neovasculature Inhibits Tumor Growth and Metastasis

Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology, Zurich, Switzerland

Requests for reprints: Dario Neri, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology, Wolfgang-Pauli-Str. 10, ETH Hönggerberg, HCI G396, CH-8093 Zurich, Switzerland. Phone: 41-44-633-74-01; Fax: 41-44-633-13-58; E-mail: neri{at}pharma.ethz.ch.

Tumor-targeting immunocytokines represent a new class of anticancer pharmaceutical agents, which often display a superior therapeutic index compared with the corresponding unconjugated cytokines. In this article, we have studied the anticancer properties of interleukin-15 (IL-15) and granulocyte macrophage colony-stimulating factor (GM-CSF), fused to the human antibody fragment scFv(L19), specific to the EDB domain of fibronectin, a marker of angiogenesis. The immunocytokines L19-IL-15 and L19-GM-CSF were expressed in mammalian cells and purified to homogeneity, revealing no loss of cytokine activity in in vitro assays. Furthermore, the ability of the two immunocytokines to selectively localize to tumors in vivo was confirmed by biodistribution analysis with radioiodinated protein preparations. L19-IL-15 and L19-GM-CSF displayed a potent antitumor activity both in s.c. and in metastatic F9 and C51 murine models of cancer in immunocompetent mice. This therapeutic action was superior compared with IL-15–based and GM-CSF–based fusion proteins, containing antibodies of irrelevant specificity in the mouse, which were used as non–tumor-targeting controls. For both L19-IL-15 and L19-GM-CSF immunocytokines, CD8⁺ T cells seemed to mostly contribute to the therapeutic action as shown by in vivo cell depletion experiments. The results presented in this article are of clinical significance, considering the fact that the sequence of EDB is identical in mouse and man and that the tumor-targeting ability of the L19 antibody has been extensively shown in clinical trials in patients with cancer. [Cancer Res 2007;67(10):4940–8]

This article has been cited by other articles:

				X. Zhu, W. D. Marcus, W. Xu, H.-i. Lee, K. Han, J. O. Egan, J. L. Yovandich, P. R. Rhode, and H. C. Wong Novel Human Interleukin-15 Agonists J. Immunol., September 15, 2009; 183(6): 3598 - 3607. [Abstract] [Full Text] [PDF]

				C. Schliemann, A. Palumbo, K. Zuberbuhler, A. Villa, M. Kaspar, E. Trachsel, W. Klapper, H. D. Menssen, and D. Neri Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2 Blood, March 5, 2009; 113(10): 2275 - 2283. [Abstract] [Full Text] [PDF]